Eli Lilly and Company (NYSE: LLY)
Indianapolis, IN 46285 (Map) Phone: 317-276-2000
Fax: 317-276-4878
http://www.lilly.com
Overview
Eli Lilly hopes everything will come up roses for you, healthwise. Although best known for its neurological therapies, the company develops medicines for a wide variety of ailments. Its top drugs include Zyprexa (schizophrenia and bipolar disorder), Cymbalta (depression), cancer treatments Gemzar and Alimta, and endocrinology (hormone-related) products such as Humalog insulin and osteoporosis medication Evista. Lilly also makes cardiovascular therapies and anti-infective agents, as well as animal health products. The company sells its products in some 140 countries.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Eli Lilly and Company (NYSE: LLY)
| Company Type | Public (NYSE: LLY) |
|---|---|
| Fiscal Year-End | December |
| 2010 Sales (mil.) | £14,916.3 |
| 1-Year Sales Growth | 5.7% |
| 2010 Net Income (mil.) | £3,276.9 |
| 1-Year Net Income Growth | 17.1% |
| 2010 Employees | 38,350 |
| 1-Year Employee Growth | (5.0%) |
Key People from Hoover's UK
Key people and executives for Eli Lilly and Company (NYSE: LLY)
| Chairman, President, and CEO | John C. Lechleiter (Subscribers see complete biographies -- view sample)
|
|---|---|
| SVP Information Technology and CIO | Michael C. (Mike) Heim |
| VP Global Communications | Jeffrey A. (Jeff) Winton |
Top Competitors from Hoover's UK
Top competitors of Eli Lilly and Company (NYSE: LLY)
There are 25 competitors for Eli Lilly; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
- Pharmaceuticals(primary)
Subsidiaries/Affiliates Covered By Hoover's UK
Subsidiaries/affiliates of Eli Lilly and Company (NYSE: LLY)
Rankings from Hoover's UK
See how Eli Lilly and Company (NYSE: LLY) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
- #115 in FORTUNE 500 (May 2011)
- S&P 500
- #115 in FORTUNE 1000 (May 2011)
- #197 in FT Global 500 (June 2011)

